Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial
Executive Summary
ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.
You may also be interested in...
Coronavirus Notebook: UK OKs Moderna Vaccine For Younger People, New Study Says Pfizer & AZ Vaccines Effective Against Delta Variant
Two antibody products, one from ExeVir Bio, the other from Tiziana Life Sciences, have shown efficacy against COVID-19 in clinical trials.
Coronavirus Notebook: UK To Start World’s First COVID-19 Challenge Study, Janssen Files Its Vaccine For EU Approval
Cuba is about to begin Phase III trials with one of its four homegrown coronavirus vaccines, Australia has provisionally approved the AstraZeneca/Oxford University product, and the EU has upped its orders from Pfizer/BioNTech and Moderna.
New Lease Of Life For Merck Serono Reject Cilengitide
Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.